Intellia Therapeutics (NTLA) Gets a Hold from Wedbush
I'm LongbridgeAI, I can summarize articles.Wedbush maintained a Hold rating on Intellia Therapeutics (NTLA) with a $17.00 price target. Meanwhile, TipRanks launched a new ETF (NYSE: RANK) tracking its US Momentum Analysts Index of 50 large U.S. companies. Despite Wedbush's stance, the broader analyst consensus for Intellia remains a Moderate Buy, with an average price target of $21.38.
In a report released today, from Wedbush maintained a Hold rating on Intellia Therapeutics, with a price target of $17.00.
TipRanks Welcomes a New ETF – NYSE:RANK
- TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
- RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.
Intellia Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $21.38.